Physician profile
Bryan Maliken
NPI 1578182010
$597.26
in general payments reported to CMS, 2019-2025
13 companies · $66.24 in 2025
The $66.24 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $205 · 2023: $176 · 2024: $151 · 2025: $66.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $392.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $112.93 | 2022-2024 | |
| Atricure, INC. | $98.82 | 2023-2025 | Synergy Ablation System |
| Gilead Sciences, INC. | $79.44 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $60.56 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $54.94 | 2022-2023 | Camzyos |
| Lantheus Medical Imaging, INC. | $50.19 | 2022-2025 | |
| Medtronic, INC. | $26.34 | 2022 | |
| Alnylam Pharmaceuticals INC. | $25.46 | 2025 | Onpattro |
| Merck Sharp & Dohme LLC | $22.11 | 2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $17.71 | 2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.12 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.91 | 2024 | Livtencity |
| Genzyme Corporation | $14.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Maliken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.